Skip to search formSkip to main contentSkip to account menu

trastuzumab

Known as: Anti-p185-HER2, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-c-ERB-2 
A monoclonal antibody that binds to HER2 (human epidermal growth factor receptor 2), and can kill HER2-positive cancer cells. Monoclonal antibodies… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in… 
Review
2012
Review
2012
BACKGROUND Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2… 
Highly Cited
2011
Highly Cited
2011
BACKGROUND Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with… 
Review
2007
Review
2007
  • C. Hudis
  • The New England journal of medicine
  • 2007
  • Corpus ID: 10626776
Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a… 
Highly Cited
2005
Highly Cited
2005
BACKGROUND We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent… 
Highly Cited
2005
Highly Cited
2005
BACKGROUND Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that… 
Highly Cited
2002
Highly Cited
2002
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic… 
Highly Cited
2002
Highly Cited
2002
Background The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine…